Efficacy and Safety of a New 20% Immunoglobulin Preparation for Subcutaneous Administration, IgPro20, in Patients With Primary Immunodeficiency

Subcutaneous human IgG (SCIG) therapy in primary immunodeficiency (PID) offers sustained IgG levels throughout the dosing cycle and fewer adverse events (AEs) compared to intravenous immunoglobulin (IVIG). A phase I study showed good local tolerability of IgPro20, a new 20% liquid SCIG stabilized wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Hagan, John B., Fasano, Mary B., Spector, Sheldon, Wasserman, Richard L., Melamed, Isaac, Rojavin, Mikhail A., Zenker, Othmar, Orange, Jordan S.
Formato: Texto
Lenguaje:English
Publicado: Springer US 2010
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2935975/
https://www.ncbi.nlm.nih.gov/pubmed/20454851
http://dx.doi.org/10.1007/s10875-010-9423-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2935975/
https://www.ncbi.nlm.nih.gov/pubmed/20454851
http://dx.doi.org/10.1007/s10875-010-9423-4

Ejemplares similares